Assessing functional tricuspid regurgitation using 3D echocardiography

The FUnctional TricUspid REgurgitation by 3D EChocardiography Cooperative Study

Observational Istituto Auxologico Italiano · NCT05747404

This study is testing a new 3D imaging method to better understand and measure the severity of tricuspid regurgitation in patients, helping doctors improve diagnosis and treatment.

Quick facts

Study typeObservational
Enrollment1500 (estimated)
Ages18 Years and up
SexAll
SponsorIstituto Auxologico Italiano Academic / other
Locations4 sites (Milan and 3 other locations)
Trial IDNCT05747404 on ClinicalTrials.gov

What this trial studies

This observational study aims to enroll patients with functional tricuspid regurgitation to establish reference outcomes and define threshold values for different grades of severity. It utilizes three-dimensional echocardiography to analyze the geometry of the right ventricle, right atrium, tricuspid annulus, and leaflets in relation to various cardiac conditions. The study also evaluates a new software package designed to measure tricuspid valve geometry and develop new parameters for assessing FTR severity. The goal is to enhance diagnostic and prognostic capabilities in patients with this condition.

Who should consider this trial

Good fit: Ideal candidates include adults over 18 with specific cardiac conditions such as atrial fibrillation, pulmonary hypertension, or right ventricular cardiomyopathy.

Not a fit: Patients with primary tricuspid valve disease or those already scheduled for tricuspid valve repair may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to improved diagnostic criteria and treatment strategies for patients with functional tricuspid regurgitation.

How similar studies have performed: While there have been studies on tricuspid regurgitation, this approach using 3D echocardiography and new software for geometry assessment is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* older than 18 years,
* signed informed consent to be part of this study,
* no pregnancy,
* the presence of at least one of the following cardiac conditions: a. Permanent atrial fibrillation b. Pulmonary arterial hypertension c. Left heart diseases with increased postcapillary pressure d. Right ventricular cardiomyopathy e. Right ventricular infarction f. Chronic thromboembolic pulmonary embolism g. Congenital diseases with right ventricular volume overload (atrial septal defect, interventricular septal defect, pulmonary regurgitation) h. Previous left heart valve surgery I. Good enough acoustic window and patient cooperation to obtain 3D echo data sets of the right ventricle, right atrium and tricuspid valve with a minimum temporal resolution of 20 vps l. Availability for clinical and echocardiography follow-up

Exclusion Criteria:

* Unwillingness to be part of the study
* Primary tricuspid valve disease
* Patient already scheduled for tricuspid valve repair/replacement
* Cardiac pacemaker, ICD or CRT leads
* Poor acoustic window
* Impossibility of left lateral decubitus position
* Extreme heart rates (\<50 or \>100 bpm)
* Previous LVAD implantation

Where this trial is running

Milan and 3 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Heart Valve IncompetenceEchocardiography, TransthoracicFunctional tricuspid regurgitationThree-dimensional echocardiographyDoppler echocardiographyRight ventricular functionRight atrial function
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.